Tobacco Documents Online

f , June 17, 1981 EFFECTS OF SENDAI VIRUS AND VACCINE ON SHORT-TERM TOXICOLOGICAL AND IMMUNOLOGICAL MARKERS IN STRAIN A/J MICE C.J. Henry, M.J. Collins, W.C. Hall, 0. Putman, R.A. Lubet ' D.R. Dansie, M.D. Avery, C. McKinney, and R.E. Kouri Microbiological Associates, 5221 River Road, Bethesda, Maryland 20016 Over the last several years, we have noticed that inadvertent infection with Sendai virus can alter interpretation of the results of chemical carcinogen bioassays in three major ways: 1) reduced survival during chemical treatment, 2) alteration in the latency and incidence of chemically induced pulmonary carcinomas, and 3) appearance of alveolar epithelial hypertrophy and hyperplasia. During preliminary cigarette smoke inhalation studies, we observed that Sendai virus infection compli- cated the morphologic appearance and interpretation of pulmonary lesions. Following vaccination against Sendai virus, we noticed that survival in- creased, that dose-response became predictable, and that proliferative alveolar epithelial lesions were reduced. What has been lacking in this area is a controlled study investigating the effects of Sendai virus and the recently developed vaccine on defined short-term and long-term end- points in a model system for chemical carcinogenesis. The following study has been implemented to address the effects of Sendai virus and vaccine on a battery of short-term markers in Strain A/J mice. Upon receipt of the animals, the mice were tested and found to be negative for serum antibody titers to Sendai virus. The mice were divided into four groups: untreated, Sendai virus infected, Sendai vaccinated, and Sendai vaccinated and infected. The vaccinated mice were immunized with Sendai vaccine 3 weeks prior to initiation of experi- mentation. Mice were lightly anesthetized and given 1 LD10 of Sendai virus (Strain P3193) intranasally. Animals were killed on days 2, 5, 9, 14, and 21. The following assays were determined in each group: a) mitogen activation of spleen cells using concanavalin A, phytohemagglutin, and E. coli lipopolysaccharide; b) Jerne plaque cell forming (PFC) assay to sheep red blood cells (SRBC) at 3, 5, and 7 days post SRBC immunizations; c) pulmonary and hepatic aryl hydrocarbon hydroxylase levels; d) pulmonary and hepatic ornithine decarboxylase levels; e) serum antibody titers against Sendai virus; f) lung virus levels; and g) the respiratory tract lesions. Results will be presented. CTR CaNTRRCTS 026723 11246473